Thoracic surgeon Daniela Molena leads clinical trials to improve outcomes for people with esophageal cancers.
At any time Memorial Sloan Kettering Cancer Center is conducting hundreds of clinical trials to improve care for many types of cancer. Use the tool below to browse our clinical trials that are currently enrolling new patients. Each listing explains the purpose of the trial, the trial’s eligibility criteria, and how to get more information.
The list below includes clinical trials for adult cancers. Please visit our pediatric cancer care section to find a pediatric clinical trial.
Researchers want to find the best dose of BMS-986458 to use alone and with rituximab to treat lymphoma. The people in this study have non-Hodgkin lymphoma (NHL) that came back or keeps growing after treatment.
Researchers want to find the best doses of RMC-6291 and RMC-6236 when given together to treat lung cancer and other types of cancer that have KRAS G12C mutations. The people in this study have advanced non-small cell lung cancer (NSCLC) or colorectal cancer with a gene mutation (change) called KRAS G12C.
Researchers are comparing taletrectinib with a placebo (inactive drug) in people with non-small cell lung cancer (NSCLC). The people in this study have stage 1B-3A NSCLC that has a ROS1 gene fusion. They have had the tumor completely removed with surgery.
Deficient mismatch repair (dMMR) happens when a cell becomes unable to repair mistakes that happen during the normal process of cell division. Standard treatments for early-stage rectal and endometrial cancer include chemotherapy, radiation therapy, and surgery. In this study, researchers are assessing the safety and effectiveness of giving the investigational immunotherapy dostarlimab first in people with locally advanced MMR rectal cancer or in people with early stage dMMR endometrial cancer and a strong desire for fertility preservation. Doctors will then evaluate patients' response to treatment before considering standard chemoradiation and/or surgery. Patients whose tumors respond completely to dostarlimab alone can be followed with close surveillance and no surgery.
Pirtobrutinib works by blocking a protein called BTK, which helps cancer cells grow and survive. By blocking this protein, pirtobrutinib may help stop cancer cells from growing and spreading. It is taken orally (by mouth).
The combination of radiation therapy and chemotherapy (chemoradiation) is a standard treatment for people with HPV-positive throat cancer. HPV is human papillomavirus and can cause throat cancer. Radiation therapy uses radiation to kill cancer cells and shrink tumors. Chemotherapy stops the growth of cancer cells, either by killing the cells or stopping them from dividing. However, this standard combination may cause severe side effects because it is given over 7 weeks. These side effects include sores in the mouth and gut, sore throat, and changes in taste.
To learn more about the purpose of this study and to find out who can join, please click here to visit ClinicalTrials.gov for a full clinical trial description.
The purpose of this study is to assess the safety and effectiveness of the investigational drug repotrectinib in children and young adults with solid tumors that have continued to grow or spread despite treatment. Repotrectinib works by targeting and blocking certain proteins that play a role in cancer growth. Some of these proteins are controlled by the ALK, ROS1, NTRK1, NTRK2, and NTRK3 genes. Researchers also think that combining repotrectinib with the chemotherapy drugs irinotecan and temozolomide may make the treatment more effective.
Breast cancer and non-small cell lung cancer (NSCLC) can spread to the cerebrospinal fluid-filled space around the brain and spinal cord. This is called leptomeningeal metastasis (LM). The effects of LM on the nervous system can be very serious.
